Table 1 Demographic and disease characteristics for the overall trial population and the digital TILs quantification subset.
S0800 | Digital TILs subgroup | |
|---|---|---|
Eligible and maintained consent | 211 | 113 |
IBC or LABC | ||
IBC | 24 (11.4%) | 10 (8.8%) |
LABC | 187 (88.6%) | 103 (91.2%) |
HR status | ||
HR+ (ER+ and/or PR+) | 144 (68.2%) | 78 (69.0%) |
HR− (ER− and PR−) | 67 (31.8%) | 35 (31.0%) |
Randomized treatment | ||
No bevacizumab | 113 (53.5%) | 59 (52.2%) |
bevacizumab | 98 (46.5%) | 54 (47.8%) |
Primary outcome | ||
RD | 152 (72.0%) | 80 (70.8%) |
pCR | 59 (28.0%) | 33 (29.2%) |
